3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%

HONG KONG, March 21, 2023 /PRNewswire/ — Chinese leading biopharmaceutical company 3SBio (01530.HK) today announced its 2022 annual results. In 2022, 3SBio’s core biopharmaceutical products posted robust growth, hair health business achieved blistering performance, and contract…